Korea-Seoul Life Science Fund
Korea-Seoul Life Science Fund is a venture capital firm established in 2011 and located in Cambridge, Massachusetts. The firm specializes in investing in life sciences companies, targeting sectors such as biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare. With a focus on opportunities in both Asia and the United States, Korea-Seoul Life Science Fund aims to support innovative companies that contribute to advancements in health and medicine.
EuBiologics Co., Ltd. is a South Korean biopharmaceutical company focused on developing and supplying vaccines aimed at addressing epidemics and antibiotic resistance. The company offers several products, including Euvchol, an oral cholera prevention vaccine, and CRM197, a diphtheria toxin mutant vaccine. In addition to its vaccine portfolio, EuBiologics provides a range of customized services related to biopharmaceutical development, encompassing mammalian and microbial cell-derived products. These services include cell line development, GMP production, validation, and regulatory support. The company also specializes in manufacturing recombinant biological products and antibody therapeutics, along with offering process, formulation, and analytical method development. Furthermore, EuBiologics provides contract testing services, which cover lot release, stability, raw material, and method validation testing. Founded in 2010 and headquartered in Seoul, EuBiologics aims to contribute to global public health through its innovative solutions.
CrystalGenomics is a leading structural chemoproteiomics-based drug discovery and development company headquartered in Seoul, Korea with a US presence (CG Pharmaceuticals, Inc.) in Emeryville, California for multi-national clinical management.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.